New hope for fighting deadly brain tumors: experimental drug combo enters testing
NCT ID NCT07326566
Summary
This study is testing whether adding a new oral drug called silevertinib to standard chemotherapy (temozolomide) helps people with a specific type of aggressive brain cancer (glioblastoma) live longer without their cancer getting worse. It will involve about 162 newly diagnosed patients who have already had surgery and radiation. The goal is to see if the drug combination is safe and more effective than the standard treatment alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.